MedTrace Logo

Study of Cannabidiol for Drug-Resistant Epilepsies

NCT03014440 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2017-04-04

No results posted yet for this study

Summary

The purpose of this study is to determine if cannabidiol is safe and effective at different doses as an additional treatment for pediatric drug-resistant epilepsy. Pure cannabidiol has potentially therapeutic properties, such as anti-convulsant effects, that may reduce seizure frequency. There are only a few open label studies that have demonstrated the safety and tolerance of cannabiodiol in both adult and pediatric epileptic populations--these studies were performed either retrospectively or with varying cannabidiol preparations. There are no well-documented studies and completely analyzed data for pediatric epileptic patients.

Conditions

  • Drug Resistant Epilepsy

Interventions

DRUG

Cannabidiol

Sponsors & Collaborators

  • University of Pittsburgh

    collaborator OTHER

  • Geisinger Clinic

    collaborator OTHER

  • Eric Marsh, MD

    lead OTHER

Eligibility

Min Age
1 Year
Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03014440 on ClinicalTrials.gov